Amneal Adds Another Complex Generic With TobraDex Approval

Expands Portfolio With Dexamethasone/Tobramycin Ophthalmic Suspension

Amneal has broadened its complex generics portfolio by gaining FDA approval for its generic version of ophthalmic combination medicine TobraDex.

Eye Data Ophthalmic
Amneal has added to its complex generics portfolio with a TobraDex rival • Source: Shutterstock

Amneal has added a further treatment to its complex generics portfolio after gaining US Food and Drug Administration approval for its abbreviated new drug application for a generic version of TobraDex (dexamethasone/tobramycin) 0.3%/0.1% ophthalmic suspension.

The approval comes as Amneal is actively pursuing higher-margin products – including complex dosage forms, drug-device combinations and other high-value...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

More from Generics Bulletin

Bio-Thera Matches Alvotech With US Golimumab Filing Acceptance

 
• By 

Bio-Thera is one step closer to launching a biosimilar to Johnson & Johnson’s Simponi in the US, following FDA acceptance of its BAT2506 proposed golimumab candidate.

Samsung Bioepis Finds New US Partner For Ophthalmic Biosimilars

 
• By 

Samsung Bioepis has announced a fresh ophthalmic biosimilars partnership with Harrow, as the end approaches for a longstanding US commercialization alliance with Biogen on the Korean firm's Lucentis (ranibizumab) and Eylea (aflibercept) rivals Byooviz and Opuviz.

‘Our Position Has Naturally Shifted’ – How Standalone Sandoz Is Taking On Originator Abuses

 
• By 

As a standalone generics and biosimilars company, Sandoz now feels freer to speak out against originator abuses of intellectual property, the firm’s global IP head Julia Pike tells Generics Bulletin, including challenges to Bayer on rivaroxaban and Amgen on etanercept.